Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer

Abstract

Lung cancer is a prominent cause of death annually. It is the most common cancer worldwide and the leading cause of cancer deaths in men and women. In this research, we focused mostly on non-small cell lung cancer (NSCLC) which is the most prevalent subtype. The primary objective of treatment strategies and patient care is to improve quality of life (QoL) and extend survival. Thus, various medications and therapies are being tested in clinical trials. Our evaluation included phase II clinical trial data because it provides a comprehensive and reliable review of safety and effectiveness. A total of 487 data were collected from a sample of 364 papers, comprising 428 overall response rate (ORR) and 374 overall survival (OS) data. To understand patients' survival and response to different treatment sizes, efficacy endpoints were evaluated and differentiated. The relationship between median age, ORR, and OS was examined using correlation analysis. Median age had a weak negative relation with OS, but ORR had a strong positive correlation. Moreover, we found that a combination of three drugs yielded the most beneficial outcome compared to therapy with one or two agents